1-Pentanol, 2-[[2-aMino-5-[[(1S)-1-phenylethyl]thio]thiazolo[4,5-d]pyriMidin-7-yl]aMino]-4-Methyl-,

Introduction：Basic information about 1-Pentanol, 2-[[2-aMino-5-[[(1S)-1-phenylethyl]thio]thiazolo[4,5-d]pyriMidin-7-yl]aMino]-4-Methyl-,, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

1-Pentanol, 2-[[2-aMino-5-[[(1S)-1-phenylethyl]thio]thiazolo[4,5-d]pyriMidin-7-yl]aMino]-4-Methyl-, (2R)- Basic information

• Product Name: 1-Pentanol, 2-[[2-aMino-5-[[(1S)-1-phenylethyl]thio]thiazolo[4,5-d]pyriMidin-7-yl]aMino]-4-Methyl-, (2R)-
• Synonyms: 1-Pentanol, 2-[[2-aMino-5-[[(1S)-1-phenylethyl]thio]thiazolo[4,5-d]pyriMidin-7-yl]aMino]-4-Methyl-, (2R)-;AZD 8797; AZD-8797;CX3CR1 antagonist 18a;AZD 8797;(R)-2-(2-AMINO-5-((S)-1-PHENYLETHYLTHIO)THIAZOLO[4,5-D]PYRIMIDIN-7-YLAMINO)-4-METHYLPENTAN-1-OL;(2R)-2-[(2-amino-5-{[(1S)-1-phenylethyl]sulfanyl}-[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentan-1-ol;AZD8797( KAND567);(R)-2-((2-Amino-5-(((S)-1-phenylethyl)thio)thiazolo[4,5-d]pyrimidin-7-yl)amino)-4-methylpentan-1-ol , AZD8797
• CAS: 911715-90-7
• MF: C19H25N5OS2
• MW: 403.56
• Mol File: 911715-90-7.mol

1-Pentanol, 2-[[2-aMino-5-[[(1S)-1-phenylethyl]thio]thiazolo[4,5-d]pyriMidin-7-yl]aMino]-4-Methyl-, (2R)- Chemical Properties

• Boiling point: 651.1±65.0 °C(Predicted)
• density: 1.31±0.1 g/cm3(Predicted)
• storage temp.: Store at -20°C
• solubility: DMSO : ≥ 150 mg/mL (371.69 mM)
• pka: 14.47±0.10(Predicted)
• form: Solid
• color: Light yellow to yellow
• InChIKey: ZMQSLMZOWVGBSM-GXTWGEPZSA-N
• SMILES: C(O)[C@H](NC1N=C(S[C@H](C2=CC=CC=C2)C)N=C2N=C(N)SC2=1)CC(C)C

1-Pentanol, 2-[[2-aMino-5-[[(1S)-1-phenylethyl]thio]thiazolo[4,5-d]pyriMidin-7-yl]aMino]-4-Methyl-, (2R)- Usage And Synthesis

Uses

(2R)-2-[[2-Amino-5-[[(1S)-1-phenylethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-1-pentanol is an allosteric non-competitive modulator of the human CX3CR1 receptor. It can be used to develop treatment for multiple sclerosis.

in vivo

AZD8797 treatment in Dark Agouti rats with myelin oligodendrocyte glycoprotein-induced EAE results in reduced paralysis, CNS pathology, and incidence of relapses. The compound is effective when starting treatment before onset, as well as after the acute phase^[2].

IC 50

CX3CR1: 3.9 nM (Ki, ¹²⁵I-CX3CL-CX3CR1 in HEK293S cells); ¹²⁵I-IL-8-CXCR2: 2800 nM (Ki, in HEK293S cells)